Phase 1 Study to Evaluate the Safety of Reducing the Prophylactic Dose of Dexamethasone around Docetaxel Infusion in Patients with Prostate and Breast Cancer.
Rieneke T LugtenbergStefanie de GrootDanny HoutsmaVincent O DezentjéAnnelie J E VulinkMaarten J FischerJohanneke E A PortieljeJacobus J M van der HoevenAndré B P van KuilenburgHanno PijlJudith R KroepPublished in: Cancers (2023)
It seems that the prophylactic dose of dexamethasone around docetaxel infusion can be safely reduced with respect to the occurrence of grade III/IV HSRs or the fluid retention syndrome.